Global Cardiac Monitoring & Cardiac Rhythm Management Devices Markets 2022-2027

Focus on ECG Devices, Implantable Loop Recorders, Mobile Cardiac Telemetry Devices, & Cardiac Output Monitoring Devices

The “Global Cardiac Monitoring & Cardiac Rhythm Management Devices Market, By Cardiac Monitoring Devices (ECG Devices, Implantable Loop Recorders, Others), By Cardiac Rhythm Management Devices, By End User, By Region, Competition Forecast & Opportunities, 2027” report has been added to ResearchAndMarkets.com’s offering.

The global cardiac monitoring & cardiac rhythm management devices market is expected to grow at a steady CAGR in the forecast period, 2023-2027

Factors such as the rise in the number of patients suffering from cardiovascular disorders and the growing geriatric population are driving the demand for the global cardiac monitoring & cardiac rhythm management devices market.

Emerging economies such as India and China are expected to provide a wide range of growth opportunities for players in the market, which is driven by their large and growing population as well as the increasing number of hospitals and clinics in these countries.

The global cardiac monitoring & cardiac rhythm management devices market is segmented into cardiac monitoring devices, cardiac rhythm management devices, end user, company, and regional distribution.

Based on cardiac monitoring devices, the market is segmented into ECG devices, implantable loop recorders, mobile cardiac telemetry devices, cardiac output monitoring devices, and others. ECG devices dominate the market and are expected to maintain their dominance through the next five years.

Growing commercialization of novel products, regional expansions, technological advancements, and government initiatives are the primary factors driving the segment demand.

Based on cardiac rhythm management devices, the market is divided into defibrillators and pacemakers. Defibrillators are expected to hold the largest market share in the forecast period, 2023-2027. The surge in the use of cardiac rhythm management devices in countries such as China and India, among others, is influencing the segmental demand.

Companies are focusing on extensive research and development activities to stay competitive in the market.

Objective of the Study:

  • To analyze historical growth in market size of global cardiac monitoring & cardiac rhythm management devices market from 2017 to 2021
  • To estimate and forecast the market size of global cardiac monitoring & cardiac rhythm management devices market from 2022E to 2027F and growth rate until 2027F
  • To classify and forecast global cardiac monitoring & cardiac rhythm management devices market based on cardiac monitoring devices, cardiac rhythm management devices, end user, company, and regional distribution
  • To identify dominant region or segment in the global cardiac monitoring & cardiac rhythm management devices market
  • To identify drivers and challenges for global cardiac monitoring & cardiac rhythm management devices market
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global cardiac monitoring & cardiac rhythm management devices market
  • To identify and analyze the profiles of leading players operating in global cardiac monitoring & cardiac rhythm management devices market
  • To identify key sustainable strategies adopted by market players in global cardiac monitoring & cardiac rhythm management devices market

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global cardiac monitoring & cardiac rhythm management devices market.

  • Abbott Laboratories, Inc
  • Medtronic PLC
  • Boston Scientific Corporation
  • MicroPort Scientific Corporation
  • GE Healthcare
  • Koninklijke Philips NV
  • Hill-Rom Holdings, Inc
  • BIOTRONIK
  • Asahi Kasei Corporation
  • Nihon Kohden Corporation
  • Schiller AG
  • Alivecor, Inc
  • Metrax GmbH
  • Shenzhen Mindray Bio-Medical Electronics
  • LivaNova PLC

Report Scope:

Years considered for this report:

  • Historical Years: 2017-2020
  • Base Year: 2021
  • Estimated Year: 2022E
  • Forecast Period: 2023F-2027F

Cardiac Monitoring & Cardiac Rhythm Management Devices Market, By Cardiac Monitoring Devices:

  • ECG Devices
  • Implantable Loop Recorders
  • Mobile Cardiac Telemetry Devices
  • Cardiac Output Monitoring Devices
  • Others

Cardiac Monitoring & Cardiac Rhythm Management Devices Market, By Cardiac Rhythm Management Devices:

  • Defibrillators
  • Pacemakers

Cardiac Monitoring & Cardiac Rhythm Management Devices Market, By End User:

  • Hospitals & Clinics
  • Cardiac Care Centers
  • Ambulatory Surgery Centers
  • Others

Cardiac Monitoring & Cardiac Rhythm Management Devices Market, By Region:

  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia

Europe

  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain

North America

  • United States
  • Mexico
  • Canada

South America

  • Brazil
  • Argentina
  • Colombia
  • Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

For more information about this report visit here.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.